Hims & Hers Health Launches Peptides+ Compounded Product Line
Hims & Hers Health (HIMS) has announced the launch of 'Peptides+', a new product line featuring up to five compounded treatments. This expansion follows recent easing of federal restrictions by the Trump administration regarding unapproved but high-demand treatment categories. The new offering includes glutathione and other peptide-based products, allowing the telehealth platform to tap into the growing market for compounded medical treatments. This move positions HIMS to capture increased consumer demand in a regulatory environment that has become more permissive toward certain types of compounding.

Tickers: $HIMS
Topics: compounded drugs peptides regulatory changes telehealth
Read the full article at Seeking Alpha
Part of the story Hims & Hers Health Launches Peptides+ Platform Featuring Compounded Longevity Treatments (2 articles)